Cargando…
To Use, or Not to Use Carbapenem When Extended-spectrum β-lactamase (ESBL)-producing Bacteria Are Isolated from Sputum Cultures, That Is the Question
Autor principal: | Miki, Makoto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849538/ https://www.ncbi.nlm.nih.gov/pubmed/29269652 http://dx.doi.org/10.2169/internalmedicine.9413-17 |
Ejemplares similares
-
Extended-Spectrum β-Lactamases (ESBL) Producing Bacteria in Animals
por: Tseng, Chien-Hao, et al.
Publicado: (2023) -
Moxalactam is not more active on extended spectrum β-lactamase (ESBL) producing bacteria than on non-ESBL producers
por: Singh, Bhoj R
Publicado: (2018) -
Extended Spectrum Beta-Lactamase (ESBL) Produced by Gram-Negative Bacteria in Trinidad and Tobago
por: Akpaka, Patrick Eberechi, et al.
Publicado: (2021) -
838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020) -
479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)